Partners and Investors

Partnership Collaboration and Investment Opportunities

Cend will enter partnerships to enable more effective solid tumor cancer delivery for a range of therapeutic modalities.


Cend Therapeutics and Qilu Pharmaceutical Announce Partnership

Cend and its collaborators have demonstrated ability to enhance delivery and antitumor activity of:

  • Antibodies, including checkpoint inhibitors
  • Antibody-drug conjugates (ADCs)
  • Adoptive cell immunotherapies, such as

CAR-T
Natural killer (NK) cell therapies
Cytotoxic T lymphocytes (CTLs)

  • Cytokines, such as IL-2 and IL-15
  • Nucleic acid-based drugs

Antisense
siRNA
microRNA
messenger RNA (mRNA)
Immunostimulatory oligonucleotides
CRISPR